Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Oct 1. pii: CD-19-0555. doi: 10.1158/2159-8290.CD-19-0555. [Epub ahead of print]

PMID:
31575541
2.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP.

Cancer Discov. 2019 Oct 1. doi: 10.1158/2159-8290.CD-19-0367. [Epub ahead of print]

PMID:
31575540
3.

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C.

Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. doi: 10.1126/scitranslmed.aao1690.

PMID:
29093181
4.

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.

Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK.

Oncotarget. 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.

5.

Structural basis of nSH2 regulation and lipid binding in PI3Kα.

Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB.

Oncotarget. 2014 Jul 30;5(14):5198-208.

6.

Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.

Zheng Z, Amran SI, Zhu J, Schmidt-Kittler O, Kinzler KW, Vogelstein B, Shepherd PR, Thompson PE, Jennings IG.

Biochem J. 2012 Jun 15;444(3):529-35. doi: 10.1042/BJ20120499.

7.

Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase.

Pinson JA, Schmidt-Kittler O, Frazzetto M, Zheng Z, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE.

Aust J Chem. 2012 Jan 10;65(10):1396-1404.

8.

Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.

Pinson JA, Schmidt-Kittler O, Zhu J, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE.

ChemMedChem. 2011 Mar 7;6(3):514-22. doi: 10.1002/cmdc.201000467. Epub 2011 Jan 4.

9.

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H.

PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812.

10.

PI3Kα inhibitors that inhibit metastasis.

Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S.

Oncotarget. 2010 Sep;1(5):339-48.

11.

Structural effects of oncogenic PI3Kα mutations.

Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM.

Curr Top Microbiol Immunol. 2010;347:43-53. doi: 10.1007/82_2010_53. Review.

12.

Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Gabelli SB, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM.

Biochim Biophys Acta. 2010 Mar;1804(3):533-40. doi: 10.1016/j.bbapap.2009.11.020. Epub 2009 Dec 2. Review.

13.

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.

Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang CH, Kinzler KW, Vogelstein B, Amzel LM.

Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):16996-7001. doi: 10.1073/pnas.0908444106. Epub 2009 Sep 23.

14.

Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.

Frazzetto M, Suphioglu C, Zhu J, Schmidt-Kittler O, Jennings IG, Cranmer SL, Jackson SP, Kinzler KW, Vogelstein B, Thompson PE.

Biochem J. 2008 Sep 15;414(3):383-90. doi: 10.1042/BJ20080512.

15.

High-resolution array comparative genomic hybridization of single micrometastatic tumor cells.

Fuhrmann C, Schmidt-Kittler O, Stoecklein NH, Petat-Dutter K, Vay C, Bockler K, Reinhardt R, Ragg T, Klein CA.

Nucleic Acids Res. 2008 Apr;36(7):e39. doi: 10.1093/nar/gkn101. Epub 2008 Mar 15.

16.

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM.

Science. 2007 Dec 14;318(5857):1744-8.

17.

Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.

Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R, Klein CA.

Cancer Cell. 2005 Sep;8(3):227-39.

18.

Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE.

Cancer Cell. 2005 Jun;7(6):561-73.

19.

Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells.

Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmüller G, Fierlbeck G, Klein CA.

Clin Cancer Res. 2004 Jan 15;10(2):531-7.

20.

From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42. Epub 2003 Jun 13.

21.

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.

Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G.

Lancet. 2002 Aug 31;360(9334):683-9.

PMID:
12241875
22.

SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples.

Stoecklein NH, Erbersdobler A, Schmidt-Kittler O, Diebold J, Schardt JA, Izbicki JR, Klein CA.

Am J Pathol. 2002 Jul;161(1):43-51. Erratum in: Am J Pathol. 2003 Dec;163(6):2645.

23.

Combined transcriptome and genome analysis of single micrometastatic cells.

Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmüller G.

Nat Biotechnol. 2002 Apr;20(4):387-92.

PMID:
11923846
24.

Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells.

Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4494-9.

Supplemental Content

Loading ...
Support Center